The UK and US have concluded a significant commercial pact that will preserve no levies on UK drug products entering the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This move ensures that import taxes on these vital products will stay at nothing for a timeframe of the next three years.
This agreement follows previous warnings to hike duties on branded pharmaceutical imports, with figures mentioned reaching double the cost.
"This agreement between the United Kingdom bolsters the worldwide climate for innovative medicines and establishes much-needed equity to American-British medicine commerce," a release noted.
Commercial Importance
Medicines represent one of the UK's most significant export categories to the United States, which is clearly the largest buyer for major British pharmaceutical firms.
Export figures indicate that in the year prior to September, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure represented a significant portion of all goods exports in that span.
"This deal secures work, increases investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The deal involves several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to increase total public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. In the past, rebates exceeded 20%.
Broader Context
The deal follows a protracted dispute between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by assertions that American customers were charged significantly more for the identical medicines than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while substantial investments have been directed toward projects in the United States.
One official publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the past decade.
